Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yipin Lu

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|April 29, 2005
Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligandsKe Ding, Jianyong Chen, Min Ji, et al.
Frontiers in Immunology|June 27, 2024
Plasma metabolites as mediators in immune cell-pancreatic cancer risk: insights from Mendelian randomizationKe Zhang, Jie Zhu, Peng Wang, et al.
Journal of Medicinal Chemistry|February 27, 2020
An Artificial Intelligence Approach to Proactively Inspire Drug Discovery with RecommendationsSteven L Rohall, Lydia Auch, Jonathan Gable, et al.
Journal of Medicinal Chemistry|June 9, 2006
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interactionKe Ding, Yipin Lu, Zaneta Nikolovska-Coleska, et al.
ACS Infectious Diseases|August 13, 2019
Structural and Biological Basis of Small Molecule Inhibition of <i>Escherichia coli</i> LpxD Acyltransferase Essential for Lipopolysaccharide BiosynthesisXiaolei Ma, Ramadevi Prathapam, Charles Wartchow, et al.
Journal of the American Chemical Society|July 21, 2005
Structure-based design of potent non-peptide MDM2 inhibitorsKe Ding, Yipin Lu, Zaneta Nikolovska-Coleska, et al.
Molecular Cancer Therapeutics|June 21, 2008
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancerSanjeev Shangary, Ke Ding, Su Qiu, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR InhibitorsPaul A Barsanti, Robert J Aversa, Xianming Jin, et al.
Journal of Molecular Biology|April 24, 2017
Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR InhibitorsYipin Lu, Mark Knapp, Kenneth Crawford, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR InhibitorsPaul A Barsanti, Yue Pan, Yipin Lu, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|April 29, 2005
Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligandsKe Ding, Jianyong Chen, Min Ji, et al.
Frontiers in Immunology|June 27, 2024
Plasma metabolites as mediators in immune cell-pancreatic cancer risk: insights from Mendelian randomizationKe Zhang, Jie Zhu, Peng Wang, et al.
Journal of Medicinal Chemistry|February 27, 2020
An Artificial Intelligence Approach to Proactively Inspire Drug Discovery with RecommendationsSteven L Rohall, Lydia Auch, Jonathan Gable, et al.
Journal of Medicinal Chemistry|June 9, 2006
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interactionKe Ding, Yipin Lu, Zaneta Nikolovska-Coleska, et al.
ACS Infectious Diseases|August 13, 2019
Structural and Biological Basis of Small Molecule Inhibition of <i>Escherichia coli</i> LpxD Acyltransferase Essential for Lipopolysaccharide BiosynthesisXiaolei Ma, Ramadevi Prathapam, Charles Wartchow, et al.
Journal of the American Chemical Society|July 21, 2005
Structure-based design of potent non-peptide MDM2 inhibitorsKe Ding, Yipin Lu, Zaneta Nikolovska-Coleska, et al.
Molecular Cancer Therapeutics|June 21, 2008
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancerSanjeev Shangary, Ke Ding, Su Qiu, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR InhibitorsPaul A Barsanti, Robert J Aversa, Xianming Jin, et al.
Journal of Molecular Biology|April 24, 2017
Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR InhibitorsYipin Lu, Mark Knapp, Kenneth Crawford, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR InhibitorsPaul A Barsanti, Yue Pan, Yipin Lu, et al.
Pageof 4